VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | MRD-directed trials & achieving MRD negativity in patients with high-risk multiple myeloma

Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, outlines MRD-directed clinical trials in transplant-eligible multiple myeloma and discusses the impact of multi-drug post-transplant consolidation and maintenance to drive MRD negativity in patients with high-risk disease, highlighting the consequences of these strategies on quality of life (QoL). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter